Tags

Type your tag names separated by a space and hit enter

The Impact of Cannabidiol on Psychiatric and Medical Conditions.
J Clin Med Res. 2020 Jul; 12(7):393-403.JC

Abstract

Cannabidiol (CBD) is a substance chemically derived from Cannabis sativa and discussed to be non-psychoactive. According to the FDA, marijuana is classified as a schedule I substance; however, hemp which is defined as extracts from marijuana including cannabinoids containing less than 0.3% tetrahydrocannabinol (THC), is excluded from that controlled substance act and available at local convenience stores in the US as it is seen as an herbal supplement. CBD is purported to be used for various medical and psychiatric conditions: depression, anxiety, post-traumatic stress disorder, Alzheimer's or other cognitive illnesses as well as pain. There is also a new trend to use CBD for the treatment of opioid use disorder. The one CBD product on the market that is FDA approved for the treatment of childhood epilepsy forms Dravet and Lennox-Gastaut syndromes is available under the name Epidiolex. There is a significant difference between this medication and the over-the-counter CBD products that contain very inconsistent strengths of CBD, if they contain it at all, and vary in percentage even from sample to sample. Frequently the so-called CBD products are not containing any CBD at all, but mostly containing THC. This article is a systematic review of literature reviewing the available clinical data on CBD, for use in various medical and psychiatric conditions with focus on a review of the pharmacology and toxicity. Resources used were ORVID, PubMed, MEDLINE, PsychINFO, EMBASE with keywords CBD, cannabidiol, hemp and cannabinoids.

Authors+Show Affiliations

Department of Psychiatry, Western Psychiatric Hospital, University of Pittsburgh, UPMC Health, Pittsburgh, PA, USA.Department of Psychiatry, Augusta University, Health Advocates PLLC, East Lansing, MI, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32655732

Citation

Oberbarnscheidt, Thersilla, and Norman S. Miller. "The Impact of Cannabidiol On Psychiatric and Medical Conditions." Journal of Clinical Medicine Research, vol. 12, no. 7, 2020, pp. 393-403.
Oberbarnscheidt T, Miller NS. The Impact of Cannabidiol on Psychiatric and Medical Conditions. J Clin Med Res. 2020;12(7):393-403.
Oberbarnscheidt, T., & Miller, N. S. (2020). The Impact of Cannabidiol on Psychiatric and Medical Conditions. Journal of Clinical Medicine Research, 12(7), 393-403. https://doi.org/10.14740/jocmr4159
Oberbarnscheidt T, Miller NS. The Impact of Cannabidiol On Psychiatric and Medical Conditions. J Clin Med Res. 2020;12(7):393-403. PubMed PMID: 32655732.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The Impact of Cannabidiol on Psychiatric and Medical Conditions. AU - Oberbarnscheidt,Thersilla, AU - Miller,Norman S, Y1 - 2020/06/25/ PY - 2020/04/09/received PY - 2020/05/25/accepted PY - 2020/7/14/entrez PY - 2020/7/14/pubmed PY - 2020/7/14/medline KW - Cannabidiol KW - Cannabis sativa KW - THC SP - 393 EP - 403 JF - Journal of clinical medicine research JO - J Clin Med Res VL - 12 IS - 7 N2 - Cannabidiol (CBD) is a substance chemically derived from Cannabis sativa and discussed to be non-psychoactive. According to the FDA, marijuana is classified as a schedule I substance; however, hemp which is defined as extracts from marijuana including cannabinoids containing less than 0.3% tetrahydrocannabinol (THC), is excluded from that controlled substance act and available at local convenience stores in the US as it is seen as an herbal supplement. CBD is purported to be used for various medical and psychiatric conditions: depression, anxiety, post-traumatic stress disorder, Alzheimer's or other cognitive illnesses as well as pain. There is also a new trend to use CBD for the treatment of opioid use disorder. The one CBD product on the market that is FDA approved for the treatment of childhood epilepsy forms Dravet and Lennox-Gastaut syndromes is available under the name Epidiolex. There is a significant difference between this medication and the over-the-counter CBD products that contain very inconsistent strengths of CBD, if they contain it at all, and vary in percentage even from sample to sample. Frequently the so-called CBD products are not containing any CBD at all, but mostly containing THC. This article is a systematic review of literature reviewing the available clinical data on CBD, for use in various medical and psychiatric conditions with focus on a review of the pharmacology and toxicity. Resources used were ORVID, PubMed, MEDLINE, PsychINFO, EMBASE with keywords CBD, cannabidiol, hemp and cannabinoids. SN - 1918-3003 UR - https://www.unboundmedicine.com/medline/citation/32655732/The_Impact_of_Cannabidiol_on_Psychiatric_and_Medical_Conditions_ L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/32655732/ DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.